A Meta-Analysis of the Antiviral Activity of the HBV-specific Immunotherapeutic TG1050 Confirms Its Value Over a Wide Range of HBsAg Levels in a Persistent HBV Pre-Clinical Model
Human Vaccines and Immunotherapeutics - United States
doi 10.1080/21645515.2018.1433970
Full Text
Open PDFAbstract
Available in full text
Date
February 22, 2018
Authors
Publisher
Informa UK Limited